Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Repligen Corporation Common Stock — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $33.19 (market cap $2.94B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.8× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is more actively traded (1,823,720 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 20 Days and Repligen Corporation Common Stock for 0 Days on average.
| FNGU | RGEN | |
|---|---|---|
Market Cap | $2.94B | $11.14B |
Volume | 1,823,720 | 1,259,263 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $194.57 |
52-Week Low | $13.73 | $102.87 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking major tech stocks, trades at $36.69 with a slight 0.22% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. The ETN provides triple exposure to tech giants like Nvidia and Apple but carries significant volatility risks as highlighted by recent analysis of its 87% decline during previous market downturns.
The outlook remains tied to the performance of underlying tech stocks, offering amplified gains in bullish markets but severe losses during corrections. Key risks include leverage decay, concentration in mega-cap tech, and market volatility. Investors should weigh the potential for high returns against the substantial downside exposure inherent in leveraged products.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
